Valneva SE
A biotechnology company that leverages its deep expertise and targeted approach to develop and commercialize preventive vaccines for infectious diseases for which no effective treatment exists. In addition to collaborating with other companies to develop a preventive vaccine candidate for Lyme disease, the company is also developing preventive vaccine candidates for chikungunya virus, COVID-19, etc. It has commercialized preventive vaccines for Japanese encephalitis and cholera.
Overview
Overview | |
|---|---|
Country | France |
State | |
Employees | 676 |
Founded | 2012 |
Financials | |
|---|---|
Market Capitalization | 528.08M |
Revenue | 166.26M |
Operating Income | 2.94M |
Operating Margin | 1.77% |
Net Income | -26.51M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 2813 / 5373 |
Sector : Healthcare | 203 / 1144 |
Industry : Biotechnology | 32 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 2949 / 5565 |
Sector : Healthcare | 434 / 1182 |
Industry : Biotechnology | 206 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 3966 / 5436 |
Sector : Healthcare | 548 / 1164 |
Industry : Biotechnology | 226 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 2746 / 5330 |
Sector : Healthcare | 273 / 1174 |
Industry : Biotechnology | 34 / 667 |